Pulmonary Eosinophilia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PLM035 MIFTS: 48	Pulmonary Eosinophilia Categories: Respiratory diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Pulmonary Eosinophilia

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia ¹² ⁵⁵ ¹⁵ ⁷³

Asthmatic Pulmonary Eosinophilia ⁷³

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the respiratory system

Other respiratory diseases principally affecting the interstitium

Pulmonary eosinophilia, not elsewhere classified

External Ids:

Disease Ontology ¹² DOID:9498

ICD9CM ³⁵ 518.3

MeSH ⁴⁴ D011657

SNOMED-CT ⁶⁸ 155623005 196145005 196147002 more

ICD10 ³³ J82

UMLS ⁷³ C0034068 C0340076

Sources

Summaries for Pulmonary Eosinophilia

Disease Ontology : ¹² A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to chronic eosinophilic pneumonia and ascaris lumbricoides infection, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Nitric Oxide and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Pulmonary Eosinophilia

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)

#	Related Disease	Score	Top Affiliating Genes
1	chronic eosinophilic pneumonia	32.3	CCL11 CCL5 IL5 RNASE3
2	ascaris lumbricoides infection	32.2	IL13 IL5
3	respiratory syncytial virus infectious disease	30.2	CCL5 IL13 IL5
4	bronchitis	30.1	CCL11 IL5 RNASE3
5	eosinophilic pneumonia	29.6	CCL11 CCL17 CCL5 IL13 IL5 RNASE3
6	eosinophilic granuloma	29.5	EPX RNASE3
7	folliculitis	29.1	CCL11 CCL5 IL4 IL5
8	pneumonia	28.5	CCL11 CCL5 IL13 IL5 SFTPD
9	interstitial lung disease	28.4	CCL17 CCL5 IL4 SFTPD
10	aspergillosis	28.4	CCL17 IL4 IL5 SFTPD
11	lung disease	28.2	CCL5 IL13 IL5 PDE4A SFTPD
12	bronchiolitis	27.8	CCL11 CCL5 IL13 IL4 IL5 RNASE3
13	allergic bronchopulmonary aspergillosis	26.9	CCL17 EPX IL4 IL5 SFTPD
14	allergic asthma	25.6	CCL11 CCL17 CCL5 EPX IL13 IL4
15	asthma	25.2	CCL11 CCL17 CCL5 EPX IL13 IL4
16	loeffler syndrome	11.9
17	loeffler endocarditis	10.7	IL5 RNASE3
18	pemphigoid gestationis	10.7	CCL11 IL5
19	chronic meningitis	10.7	CCL11 IL5
20	cow milk allergy	10.7	IL5 RNASE3
21	maxillary sinusitis	10.6	CCL5 RNASE3
22	cellulitis	10.6	IL5 RNASE3
23	cytokine deficiency	10.6	IL13 IL5
24	egg allergy	10.6	IL4 IL5
25	vulvovaginitis	10.6	CCL11 CCL5
26	sinusitis	10.6	IL5 RNASE3
27	scleritis	10.6	IL4 IL5
28	angioimmunoblastic lymphadenopathy with dysproteinemia	10.5	IL13 IL5
29	trichinosis	10.5	IL4 IL5
30	non-suppurative otitis media	10.5	IL4 IL5
31	papillary conjunctivitis	10.5	CCL11 IL4
32	cercarial dermatitis	10.5	IL4 IL5
33	toxic oil syndrome	10.5	IL4 IL5
34	primary amebic meningoencephalitis	10.5	IL4 IL5
35	radiculopathy	10.5	CCL5 IL5
36	wells syndrome	10.5	IL5 RNASE3
37	blepharitis	10.5	CCL11 IL4
38	african tick-bite fever	10.5	CCL5 IL13
39	penicillin allergy	10.4	IL13 IL4
40	vasculogenic impotence	10.4	PDE4A RNASE3
41	orofacial granulomatosis	10.4	CCL5 IL4
42	yellow fever	10.4	CCL5 IL5
43	beta-lactam allergy	10.3	IL13 IL4
44	necatoriasis	10.3	CCL17 IL5
45	status asthmaticus	10.3	CCL5 IL5 RNASE3
46	genital herpes	10.3	CCL5 IL4
47	esophageal disease	10.3	IL13 IL5
48	cough variant asthma	10.3	IL4 IL5 RNASE3
49	intrinsic asthma	10.3	IL4 IL5 RNASE3
50	atopic keratoconjunctivitis	10.3	IL4 IL5 RNASE3

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 16)

Active Peptic Ulcer Disease	Acute Cystitis
Bronchitis	Chronic Kidney Failure
Chronic Myocardial Ischemia	Decubitus Ulcer
Deficiency Anemia	Esophagitis
Familial Atrial Fibrillation	Heart Disease
Iron Deficiency Anemia	Ischemic Heart Disease
Postinflammatory Pulmonary Fibrosis	Protein-Energy Malnutrition
Respiratory Failure	Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:

Sources

Symptoms & Phenotypes for Pulmonary Eosinophilia

UMLS symptoms related to Pulmonary Eosinophilia:

hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.76	IL4 IL5 SFTPD CCL11 CCL17 CCL5
2	immune system	MP:0005387	9.61	IL4 IL5 PDE4A SFTPD CCL11 CCL17
3	respiratory system	MP:0005388	9.02	IL13 IL4 IL5 SFTPD CCL11

Sources

Drugs & Therapeutics for Pulmonary Eosinophilia

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nitric Oxide

Approved

Phase 4

10102-43-9

145068 160954

Omalizumab

Approved, Investigational

Phase 4

242138-07-4

Ciclesonide

Approved, Investigational

Phase 4

126544-47-6, 141845-82-1

444033

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3

50-24-8

5755

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3

83-43-2

6741

Budesonide

Approved

Phase 4

51333-22-3

63006 5281004

Prednisolone acetate

Phase 4,Phase 3

glucocorticoids

Phase 4,Phase 2,Phase 3

Respiratory System Agents

Phase 4,Phase 3,Phase 2

Methylprednisolone acetate

Phase 4,Phase 3

Methylprednisolone Hemisuccinate

Phase 4,Phase 3

Adrenergic Agents

Phase 4,Phase 2

Adrenergic Agonists

Phase 4,Phase 2

Adrenergic beta-2 Receptor Agonists

Phase 4,Phase 2

Adrenergic beta-Agonists

Phase 4,Phase 2

Albuterol

Phase 4,Phase 2

Gastrointestinal Agents

Phase 4

Neuroprotective Agents

Phase 4

Neurotransmitter Agents

Phase 4,Phase 2

Tocolytic Agents

Phase 4,Phase 2

Hormone Antagonists

Phase 4,Phase 2,Phase 3

Hormones

Phase 4,Phase 2,Phase 3

Anti-Allergic Agents

Phase 4,Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 3

Anti-Asthmatic Agents

Phase 4,Phase 3,Phase 2

Peripheral Nervous System Agents

Phase 4,Phase 2

Antibodies

Phase 4,Phase 3,Phase 2

Immunoglobulins

Phase 4,Phase 3,Phase 2

Antibodies, Monoclonal

Phase 4,Phase 3,Phase 2

Prednisolone hemisuccinate

Phase 4,Phase 3

Prednisolone phosphate

Phase 4,Phase 3

Antiemetics

Phase 4

Protective Agents

Phase 4

Anti-Inflammatory Agents

Phase 4,Phase 2,Phase 3

Autonomic Agents

Phase 4,Phase 2

Bronchodilator Agents

Phase 4,Phase 2

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 3

Fluorodeoxyglucose F18

Phase 4

Radiopharmaceuticals

Phase 4

Prednisone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3

53-03-2

5865

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Pharmaceutical Solutions

Phase 3,Phase 2

Immunoglobulin G

Phase 3

Citrate

Nutraceutical

Phase 3

Fluticasone

Approved, Experimental, Investigational

Phase 2

90566-53-3

62924

Salmeterol xinafoate

Phase 2

94749-08-3

56801

Fluticasone Propionate, Salmeterol Xinafoate Drug Combination

Phase 2

Dermatologic Agents

Phase 2

Indoleacetic Acids

Phase 2

Daptomycin

Approved, Investigational

103060-53-3

16129629

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia	Completed	NCT00632554	Phase 4	prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2	Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients	Completed	NCT02654145	Phase 4	Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
3	Small Particle Steroids in Refractory Asthma	Completed	NCT01171365	Phase 4	Ciclesonide;Placebo
4	An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation	Recruiting	NCT02937168	Phase 4	Reslizumab;Fludeoxyglucose F 18 (FDG);Placebo
5	The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma	Recruiting	NCT03034005	Phase 4	Budesonide
6	A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma	Completed	NCT01285323	Phase 3	Reslizumab;Placebo
7	A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma	Completed	NCT01287039	Phase 3	Reslizumab;Placebo
8	A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma	Completed	NCT01270464	Phase 3	Reslizumab;Placebo
9	Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control	Completed	NCT02281318	Phase 3	Placebo;SOC
10	Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma	Completed	NCT02559791	Phase 2, Phase 3	Placebo
11	Study of Mepolizumab Autoinjector in Asthmatics	Completed	NCT03099096	Phase 3	Mepolizumab
12	Study of Mepolizumab Safety Syringe in Asthmatics	Completed	NCT03021304	Phase 3	Mepolizumab
13	Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma	Completed	NCT01508936	Phase 3	Reslizumab;Placebo
14	A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects	Completed	NCT02135692	Phase 3	SOC
15	Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients	Recruiting	NCT02555371	Phase 3	Placebo
16	Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)	Recruiting	NCT02836496	Phase 3	Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
17	Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies	Not yet recruiting	NCT03470311	Phase 3
18	Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma	Not yet recruiting	NCT03557307	Phase 3
19	Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma	Terminated	NCT01290887	Phase 3	Reslizumab
20	Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study	Terminated	NCT02594332	Phase 3	Mepolizumab;Placebo
21	A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma	Terminated	NCT03052725	Phase 3	reslizumab
22	A Phase IIa Study of KHK4563	Completed	NCT01412736	Phase 2	KHK4563;KHK4563;KHK4563;Placebo
23	Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	Completed	NCT01312961	Phase 2	Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
24	Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children	Completed	NCT02377427	Phase 2	Mepolizumab
25	Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma	Recruiting	NCT03469934	Phase 2	ANB020;Placebo
26	Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma	Recruiting	NCT02560610	Phase 2	OC000459;Placebo
27	Effect of Benralizumab in Atopic Dermatitis	Not yet recruiting	NCT03563066	Phase 2	Benralizumab;Placebo Control
28	Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia	Unknown status	NCT01152424
29	Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma	Completed	NCT03453021		Mepolizumab
30	Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center	Completed	NCT03209934
31	Exploring Asthma Exacerbations in Mepolizumab Treated Patients	Recruiting	NCT03324230
32	Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma	Recruiting	NCT03563521
33	Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab	Recruiting	NCT03369574		Reslizumab
34	European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank	Recruiting	NCT02852928
35	Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)	Recruiting	NCT03373045

Search NIH Clinical Center for Pulmonary Eosinophilia

Sources

Genetic Tests for Pulmonary Eosinophilia

Sources

Anatomical Context for Pulmonary Eosinophilia

MalaCards organs/tissues related to Pulmonary Eosinophilia:

⁴¹

Lung, T Cells, Bone, Testes, Bone Marrow, Heart, B Cells

Sources

Publications for Pulmonary Eosinophilia

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 295)

#	Title	Authors	Year
1	Filarial Tropical Pulmonary Eosinophilia: a condition masquerading Asthma, a series of 12 cases. ( 29969926 )	Tsanglao W.R....Sharma A.	2018
2	Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. ( 28454572 )	Hirano T....Ichinose M.	2017
3	Pulmonary Eosinophilia ( 29261977 )	Salahuddin M....Cherian S.V.	2017
4	Pulmonary Eosinophilia From Inhaled Colistin. ( 28065254 )	LAcpine P.A....Boulet L.P.	2017
5	Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. ( 28488945 )	Randev S....Guglani V.	2017
6	The Rare Complication and Diagnostic Challenges of Pulmonary Eosinophilia in Graft versus Host Disease Patients after Hematopoietic Stem Cell Transplantation. ( 29058073 )	Tawfik P....Arndt P.	2017
7	Tropical pulmonary eosinophilia: effect of addition of corticosteroids after failure of diethylcarbamazine therapy. ( 28198995 )	Madan M....Chhabra S.K.	2017
8	In vivo neutralization of I+4 and I^7 integrins inhibits eosinophil trafficking and prevents lung injury during tropical pulmonary eosinophilia in mice. ( 28736941 )	Sharma P....Srivastava M.	2017
9	Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. ( 27445539 )	Saint-Pierre M.D....Moran-Mendoza O.	2016
10	Pulmonary eosinophilia associated to treatment with natalizumab. ( 27512514 )	Curto E....DomA-nguez-A8lvarez M.M.	2016
11	Concurrent sensitization to Aspergillus Fumigatus in tropical pulmonary eosinophilia. ( 27374215 )	Chhabra S.K....Dash D.J.	2016
12	Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. ( 26489428 )	Sharma P....Srivastava M.	2015
13	Simple pulmonary eosinophilia associated with clozapine treatment. ( 25514065 )	Hashimoto N....Kusumi I.	2015
14	Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. ( 26044350 )	Liu J....Liu B.	2015
15	An Unusual Case of Foreign Body Aspiration Masquerading as Pulmonary Eosinophilia. ( 26266154 )	Gopathi N.R....Kolaparthy L.	2015
16	A rare presentation of hydropneumothorax in tropical pulmonary eosinophilia: cavitation and pneumonic consolidation in a child. ( 26376823 )	Kumar S....Beri R.S.	2015
17	Simple pulmonary eosinophilia found on follow-up computed tomography of oncologic patients. ( 25082475 )	Kim S.J....Sun J.S.	2014
18	Tropical pulmonary eosinophilia--a review. ( 24135173 )	Mullerpattan J.B....Udwadia F.E.	2013
19	Pulmonary eosinophilia caused by testosterone cypionate. ( 23998379 )	Monclou GarzA^n E....Urbano Salcedo A.	2013
20	A rare case of ethambutol induced pulmonary eosinophilia. ( 24250213 )	Saha K....Jash D.	2013
21	Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. ( 23926350 )	Durant L.R....Openshaw P.J.	2013
22	Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. ( 22331917 )	Yasuda K....Nakanishi K.	2012
23	Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. ( 22252873 )	Murdock B.J....Huffnagle G.B.	2012
24	FICZ, a tryptophan photoproduct, suppresses pulmonary eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-induced allergic asthma. ( 22561122 )	Jeong K.T....Park J.H.	2012
25	Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. ( 22172479 )	Ray S....Maitra S.	2012
26	Role of oxidants in interstitial lung diseases: pneumoconioses, constrictive bronchiolitis, and chronic tropical pulmonary eosinophilia. ( 22131646 )	Rom W.N.	2011
27	Regulator of calcineurin 1 (Rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice. ( 21741935 )	Yang Y.J....Lin T.J.	2011
28	Acquired alpha 1-antitrypsin deficiency in tropical pulmonary eosinophilia. ( 21808138 )	Ray D....Kumaraswami V.	2011
29	A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. ( 21160052 )	Fritz D.K....Richards C.D.	2011
30	Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. ( 20719375 )	Kim H.R....Park D.S.	2010
31	Chlorogenic acid suppresses pulmonary eosinophilia, IgE production, and Th2-type cytokine production in an ovalbumin-induced allergic asthma: activation of STAT-6 and JNK is inhibited by chlorogenic acid. ( 20637839 )	Kim H.R....Park J.H.	2010
32	Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study. ( 21092270 )	Vaickus L.J....Remick D.G.	2010
33	Serum C3d levels in tropical pulmonary eosinophilia. ( 20424307 )	Ray D....Ramanathan V.D.	2010
34	Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. ( 19594395 )	Stevens W.W....Braciale T.J.	2009
35	Pulmonary eosinophilia. ( 19618037 )	Campos L.E....Pereira L.F.	2009
36	Enhancement of ovalbumin-induced pulmonary eosinophilia by intranasal administration of alpha1-proteinase inhibitor type 2 antisense oligonucleotides. ( 19111575 )	Sung H.N....Park J.H.	2009
37	Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. ( 18094193 )	Castilow E.M....Varga S.M.	2008
38	Pulmonary eosinophilia correlates with allergen deposition to the lower respiratory tract in a mouse model of asthma. ( 18537985 )	Siddiqui S....Silbart L.K.	2008
39	Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. ( 17996260 )	RiihimAoki M....Pringle J.	2008
40	Tropical pulmonary eosinophilia in a patient undergoing open heart surgery. ( 18285744 )	Shirin T....Mahmud R.	2008
41	The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. ( 19017987 )	Olson M.R....Varga S.M.	2008
42	Pulmonary eosinophilia. ( 18197481 )	Katz U....Shoenfeld Y.	2008
43	Transient pulmonary eosinophilia incidentally found on low-dose computed tomography: findings in 40 individuals. ( 18303297 )	Kim H.Y....Lee J.H.	2008
44	Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. ( 18519743 )	Johnson T.R....Graham B.S.	2008
45	A carbohydrate fraction, AIP1 from Artemisia iwayomogi suppresses pulmonary eosinophilia and Th2-type cytokine production in an ovalbumin-induced allergic asthma. Down-regulation of TNF-alpha expression in the lung. ( 18068107 )	Lee J.A....Park J.H.	2008
46	The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. ( 18242596 )	Kudlacz E....Changelian P.	2008
47	C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. ( 17079327 )	Melendi G.A....Polack F.P.	2007
48	A critical role for Pin1 in allergic pulmonary eosinophilia in rats. ( 17720236 )	Esnault S....Malter J.S.	2007
49	Eosinophilic pustular folliculitis associated with pulmonary eosinophilia. ( 17714146 )	Yoneda K....Kubota Y.	2007
50	Tropical pulmonary eosinophilia: a rare cause of cough in immigrants to Australia. ( 17908009 )	Yong M.K....Eisen D.P.	2007

Sources

Genes for Pulmonary Eosinophilia

Genes related to Pulmonary Eosinophilia (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	IL5	Interleukin 5	Protein Coding	34.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1475542 10030835 7613159 (more) 17996260 10590259 11046102 11713356 7921434 8664444 8784786 8985399 9712797 15905537
2	RNASE3	Ribonuclease A Family Member 3	Protein Coding	33.34	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11181646 16114131 16014847 (more) 9032176 11348936
3	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	33.07	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8784786
4	IL4	Interleukin 4	Protein Coding	30.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1475542 10030835 15158774 (more) 17940489 17996260 9352584 7921434 8985399
5	IL13	Interleukin 13	Protein Coding	29.87	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16120093 15905537
6	PDE4A	Phosphodiesterase 4A	Protein Coding	25.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9802959
7	EPX	Eosinophil Peroxidase	Protein Coding	22.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	8818342
8	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	21.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	20.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	SFTPD	Surfactant Protein D	Protein Coding	20.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	16114131 12706535 15905537

Sources

Variations for Pulmonary Eosinophilia

Sources

Expression for Pulmonary Eosinophilia

Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Sources

Pathways for Pulmonary Eosinophilia

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 23)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.75	CCL11 CCL5 EPX IL13 IL4 IL5
2	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.4	CCL11 CCL17 CCL5 IL13 IL4 IL5
3	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.26	CCL11 CCL17 CCL5 IL13 IL4 IL5
4	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.16	CCL11 CCL17 CCL5 IL13 IL4 IL5
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.1	CCL11 CCL5 IL13 IL4 IL5
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.04	CCL11 CCL17 CCL5 IL13 IL4 IL5
7	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.59	CCL11 EPX IL13 IL4 IL5 RNASE3
8	Th17 cell differentiation ³⁷ Show member pathways Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.2	IL13 IL4 IL5
9	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁷ Interleukin-17 signaling ⁶⁶ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.05	CCL11 CCL17 IL13 IL4 IL5
10	Bacterial infections in CF airways ²² Show member pathways IL-1 beta-dependent CFTR expression ²² Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²²	11.97	CCL11 IL4 SFTPD
11	Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	11.81	CCL11 CCL17 CCL5
12	Interleukin-4 and 13 signaling ⁶⁶	11.79	CCL11 IL13 IL4
13	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.65	CCL11 CCL17 CCL5 IL13 IL4 IL5
14	Glucocorticoid receptor regulatory network ¹	11.61	IL13 IL4 IL5
15	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.59	IL13 IL4 IL5
16	IL4-mediated signaling events ¹	11.36	CCL11 CCL17 IL4 IL5
17	Interleukin-10 signaling ⁶⁶	11.34	CCL5 IL13 IL4
18	Lung fibrosis ¹	11.15	CCL11 CCL5 IL13 IL4 IL5
19	Development and heterogeneity of the ILC family ¹	11.14	IL13 IL4 IL5
20	Inflammatory Response Pathway ¹	11.12	IL4 IL5
21	Cytokines and Inflammatory Response ¹	11.09	IL13 IL4 IL5
22	OX40 Pathway ⁶⁴	11	IL13 IL4 IL5
23	Th2 Differentiation Pathway ⁶⁵	10.68	CCL11 CCL17 IL13 IL4 IL5

Sources

GO Terms for Pulmonary Eosinophilia

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.61	CCL11 CCL17 CCL5 EPX IL13 IL4
2	extracellular space	GO:0005615	9.28	CCL11 CCL17 CCL5 EPX IL13 IL4

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.77	CCL11 CCL17 CCL5
2	defense response to bacterium	GO:0042742	9.76	EPX RNASE3 SFTPD
3	chemotaxis	GO:0006935	9.73	CCL11 CCL17 CCL5
4	cellular response to tumor necrosis factor	GO:0071356	9.72	CCL11 CCL17 CCL5
5	cellular response to interferon-gamma	GO:0071346	9.7	CCL11 CCL17 CCL5
6	cellular response to interleukin-1	GO:0071347	9.69	CCL11 CCL17 CCL5
7	chemokine-mediated signaling pathway	GO:0070098	9.65	CCL11 CCL17 CCL5
8	inflammatory response	GO:0006954	9.65	CCL11 CCL17 CCL5 IL13 IL5
9	neutrophil chemotaxis	GO:0030593	9.63	CCL11 CCL17 CCL5
10	negative regulation of endothelial cell apoptotic process	GO:2000352	9.59	IL13 IL4
11	positive regulation of JAK-STAT cascade	GO:0046427	9.58	CCL5 IL5
12	monocyte chemotaxis	GO:0002548	9.58	CCL11 CCL17 CCL5
13	eosinophil chemotaxis	GO:0048245	9.57	CCL11 CCL5
14	cytokine-mediated signaling pathway	GO:0019221	9.55	CCL11 CCL5 IL13 IL4 IL5
15	macrophage chemotaxis	GO:0048246	9.54	CCL5 SFTPD
16	positive regulation of B cell proliferation	GO:0030890	9.54	IL13 IL4 IL5
17	lymphocyte chemotaxis	GO:0048247	9.5	CCL11 CCL17 CCL5
18	induction of bacterial agglutination	GO:0043152	9.49	RNASE3 SFTPD
19	negative regulation of complement-dependent cytotoxicity	GO:1903660	9.43	IL13 IL4
20	immune response	GO:0006955	9.43	CCL11 CCL17 CCL5 IL13 IL4 IL5
21	regulation of signaling receptor activity	GO:0010469	9.1	CCL11 CCL17 CCL5 IL13 IL4 IL5

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chemokine activity	GO:0008009	9.43	CCL11 CCL17 CCL5
2	lipopolysaccharide binding	GO:0001530	9.37	RNASE3 SFTPD
3	cytokine receptor binding	GO:0005126	9.32	IL13 IL4
4	CCR4 chemokine receptor binding	GO:0031729	9.16	CCL17 CCL5
5	CCR chemokine receptor binding	GO:0048020	9.13	CCL11 CCL17 CCL5
6	cytokine activity	GO:0005125	9.1	CCL11 CCL17 CCL5 IL13 IL4 IL5

Sources

Sources for Pulmonary Eosinophilia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia